Abstract 125P
Background
Approximately 20% of patients at diagnosis, and about 30–40% of patients with an initial diagnosis of localized sarcoma will develop distant metastasis and will eventually succumb to the disease. Available therapeutic lines for soft tissue sarcomas are diverse, each offering a set of specific characteristics. Beyond first-line, disease control is modest, with median progression-free survival (PFS) ranging 2.6–4.6 months. In this case, the value of trabectedin has been emphasized beyond the first line in the treatment of metastatic soft tissue sarcomas. Trabectedin is a marine-derived alkaloid, approved for the treatment of advanced STS after anthracyclines and ifosfamide.
Methods
Retrospective review of the medical records of patients who have received trabectedin in the last 5 years. A descriptive analysis has been conducted on the age at presentation, histological subtype, initial onset, and the chemotherapy line in which trabectedin was administered. In a subsequent step, the PFS and overall survival (OS) of the treated patients were analyzed. Additionally, a specific analysis was conducted on the subgroup that received a combination with radiotherapy.
Results
We included 207 patients (p). 116p women (56%). The median age 56 years. The most common metastatic site are lungs (68,6%). The most common subtypes were leiomyosarcoma (Lei) 38,2%, liposarcoma (L) 21,3%, Undifferentiated Pleomorphic Sarcoma (UPS) 10,1%, sinovial sarcoma (SiS) 6,8% and stromal sarcomas (StS) 4,3%. 73 p get treatment at second line, and 75 p get trabectedin in third line. PFS in all p is around 6 months influenced due to time p get treatment. PFS in p treated at 2° line 14 month, 6 month as 3° line, and lower in subsequences lines. p = 0,001. The different is also observed in OS. The different subtypes presented with different PFS, 10 month in ESF, 9 month in L, 8 month in Lei, 8 months in StS and 3 moths in UPS.
Conclusions
All patients treated showed benefit with PFS 6 month, higher than literature review. However, there are significance different with a higher PFS in patient with lower number of previous lines. There are some histotype with higher benefit L, leiomyosarcoma an synovial sarcoma. Trabectedin is a useful second line, with benefit in all subtypes, showing a high disease control over 4 month.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.